Relay Therapeutics, Inc. Accrued Liabilities, Current
Relay Therapeutics, Inc. (RLAY) had Accrued Liabilities, Current of $34.08 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current
us-gaap:AccruedLiabilitiesCurrent · last filed 2026-08-06
- 2026-06-30: Accrued Liabilities, Current $34.08M.
- 2026-03-31: Accrued Liabilities, Current $20.91M.
- 2025-12-31: Accrued Liabilities, Current $13.64M.
- 2025-09-30: Accrued Liabilities, Current $25.13M.
| Period end | Accrued Liabilities, Current | Accrued Liabilities, Current as first filed |
|---|---|---|
| 2026-06-30 | $34.08M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $20.91M 10-Q · filed 2026-05-05 | |
| 2025-12-31 | $13.64M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $25.13M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $23.21M 10-Q · filed 2025-08-07 | |
| 2025-03-31 | $20.99M 10-Q · filed 2025-05-05 | |
| 2024-12-31 | $21.24M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $33.22M 10-Q · filed 2024-11-06 | |
| 2024-06-30 | $27.77M 10-Q · filed 2024-08-06 | |
| 2024-03-31 | $22.36M 10-Q · filed 2024-05-02 | |
| 2023-12-31 | $14.89M 10-K · filed 2025-02-26 | |
| 2023-09-30 | $31.49M 10-Q · filed 2023-11-02 | |
| 2023-06-30 | $26.91M 10-Q · filed 2023-08-08 | |
| 2023-03-31 | $28.05M 10-Q · filed 2023-05-04 | |
| 2022-12-31 | $22.70M 10-K · filed 2024-02-22 | |
| 2022-09-30 | $29.36M 10-Q · filed 2022-11-03 | |
| 2022-06-30 | $22.11M 10-Q · filed 2022-08-04 | |
| 2022-03-31 | $15.22M 10-Q · filed 2022-05-05 | |
| 2021-12-31 | $13.56M 10-K · filed 2023-02-23 | $13.95M 10-K · filed 2022-02-24 |
| 2021-09-30 | $20.10M 10-Q · filed 2021-11-10 | |
| 2021-06-30 | $15.40M 10-Q · filed 2021-08-12 | |
| 2021-03-31 | $8.87M 10-Q · filed 2021-05-13 | |
| 2020-12-31 | $5.76M 10-K · filed 2022-02-24 | |
| 2020-09-30 | $9.68M 10-Q · filed 2020-11-12 | |
| 2020-06-30 | $8.56M 10-Q · filed 2020-08-27 | |
| 2019-12-31 | $3.75M 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |